Novel blindness gene therapy shows promise in first-in-human trial
The lowest dose of the gene therapy was shown to be safe and somewhat improved vision in the first three patients treated in the trial.
List view / Grid view
The lowest dose of the gene therapy was shown to be safe and somewhat improved vision in the first three patients treated in the trial.
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
The Champalimaud Vision Award has been awarded to research teams for the development of a gene therapy...